DexCom's Q4 2025 earnings soar: Because nothing boosts revenue like turning every meal into a wearable guilt trip

DexCom, Inc., a leading manufacturer of continuous glucose monitoring systems, reported its Q4 2025 earnings in a recent conference call. On the call, management discussed the company's financial performance, highlighting a significant increase in revenue driven by strong demand for its products. As of December 2025, DexCom's revenue reached $1.43 billion, up 25% from the same period in 2024. The company's CEO, Kevin Sayer, attributed the growth to the expanding diabetes market and increasing adoption of continuous glucose monitoring technology. DexCom's products, such as the G6 and G7 systems, have been widely adopted by healthcare professionals and patients, contributing to the company's success. The Q4 earnings report demonstrates DexCom's position as a leader in the medical technology industry, with a strong focus on innovation and customer satisfaction. With its solid financial foundation, DexCom is well-positioned for continued growth and expansion in the global diabetes care market.